Skip to content

Comparison of Efficacy and Safety of Combined Red and Blue Light with Intense Pulsed Light (400-600 nm/800-1200 nm) Plus Isotretinoin or Doxycycline in the Treatment of Moderate-to-Severe Acne

Comparison of Efficacy and Safety of Combined Red and Blue Light with Intense Pulsed Light (400-600 nm/800-1200 nm) Plus Isotretinoin or Doxycycline in the Treatment of Moderate-to-Severe Acne

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107064
Enrollment
Unknown
Registered
2025-08-04
Start date
2025-08-05
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris

Interventions

Doxycycline group:Patients received oral doxycycline (50-100 mg/day) for 6 weeks (product of Baotong Pharmaceutical Co., Ltd., Jiangsu Province)
the dosage was adjusted based on adverse events. Meanwhile, the left side of the face received combined red and blue light therapy twice weekly, utilizing red light at 625nm ± 10nm and blue light at 4
The isotretinoin group:Patients received oral low-dose isotretinoin (10-20 mg/day, 0.13-0.36 mg/kg/day
Donghai Pharmaceutical, Shanghai, China) for 6 weeks, with administration advised with meals to reduce the risk of gastrointestinal side effects and enhance drug absorption
the dosage was adjusted based on adverse events. Meanwhile, the lef

Sponsors

The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, gender not specified; 2. Meets the diagnosis of moderate-to-severe (acne vulgaris) according to the Global Acne Grading System (GAGS) score; 3. Capable of understanding and voluntarily signing a written informed consent form, able to complete treatment and follow-up as required.

Exclusion criteria

Exclusion criteria: 1.Pregnant or breastfeeding; 2.History of hypertrophic scars or keloids; 3.Received skin resurfacing treatments (including laser or chemical peels) or systemic corticosteroids or isotretinoin within 6 months prior to the first treatment; 4. Systemic diseases, such as immunodeficiency disorders, diabetes, lupus, etc.; 5. Neurological or psychiatric disorders. 6. During the study, patients were informed not to use any other acne treatments.

Design outcomes

Primary

MeasureTime frame
Global Acne Grading System;

Secondary

MeasureTime frame
Percentage of Lesion Reduction;Efficacy Rate;Evaluation of Subject Satisfaction;

Countries

China

Contacts

Public ContactMin Li

The Fourth Affiliated Hospital of Soochow University (Dushuhu Hospital, Suzhou)

lm@suda.edu.cn+86 189 3614 0383

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026